1Kaminski M S,Tuck M,Estes J,et al.131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma[].The New England Journal of Medicine.2005
2Conconi A,Martinelli G,Thieblemont C,et al.Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type[].Blood.2003
3Gopal AK,Gooley TA,Maloney DG,et al.High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma[].Blood.2003
4Cheson BD.Radioimmunotherapy of non-Hodgkin lymphomas[].Current Drug Targets.2006
5Marcus R,Imrie K,Belch A,et al.CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma[].Blood.2005
6Hiddemann W,Kneba M,Dreyling M,et al.Frontline therapy with rituximab addedto the combination of cyclophosphamide,doxorubicin,vincrestine,and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone[].Blood.2005
7Gheilmini M,Schimitz SF,Cogliatti SB,et al.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x4schedule[].Blood.2004
8Czuczman MS,Weaver R,Alkuzweny B,et al.Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy:9-year follow-up[].Journal of Clinical Oncology.2004
9Witzig TE,Flinn IW,Gordon LI,et al.Treatment.with ibritumomab tiuxetan radioimmunotherapy inpatients with rituximab-refractory follicular non-Hodgkin’s lymphoma[].Journal of Clinical Oncology.2002
10Lenz G,Dreyling M,Hoster E,et al.Immunochemotherapy with rituximab and cyclophosphamide,doxorubicin,vincristine,and prednisone significantly improves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma[].Journal of Clinical Oncology.2005
